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Background: Ugandan national guidelines recommend initiation of combination antiretroviral therapy (cART)
at CD4+ T cell (CD4) count below 350 cell/μl, but the implementation of this is limited due to availability of
medication. However, cART initiation at higher CD4 count increases survival, albeit at higher lifetime treatment
cost. This analysis evaluates the cost-effectiveness of initiating cART at a CD4 count between 250–350 cell/μl (early)
versus <250 cell/μl (delayed).
Methods: Life expectancy of cART-treated patients, conditional on baseline CD4 count, was modeled based on
published literature. First-line cART costs $192 annually, with an additional $113 for patient monitoring. Delaying
initiation of cART until the CD4 count falls below 250 cells/μl would incur the cost of the bi-annual CD4 count
tests and routine maintenance care at $85 annually. We compared lifetime treatment costs and disability adjusted
life-expectancy between early vs. delayed cART for ten baseline CD4 count ranges from 250-350 cell/μl. All costs
and benefits were discounted at 3% annually.
Results: Treatment delay varied from 6–18 months. Early cART initiation increased life expectancy from 1.5-3.5 years
and averted 1.33–3.10 disability adjusted life years (DALY’s) per patient. Lifetime treatment costs were $4,300–$5,248
for early initiation and $3,940–$4,435 for delayed initiation. The cost/DALY averted of the early versus delayed start
ranged from $260–$270.
Conclusions: In HIV-positive patients presenting with CD4 count between 250-350 cells/μl, immediate initiation of
cART is a highly cost-effective strategy using the recommended one-time per capita GDP threshold of $490
reported for Uganda. This would constitute an efficient use of scarce health care funds.
Keywords: HAART, Economics, Mortality, Adverse effectsBackground
Currently, combination antiretroviral therapy (cART) is
the only effective treatment for HIV. This therapy
reduces HIV-related morbidity and mortality in the indi-
vidual patient and can also prevent transmission of HIV
to the uninfected population [1-4]. Although cART is
clearly beneficial, access to this treatment is limited by a
lack of resources, particularly in low-income countries.
In western countries, treatment guidelines recommend
treatment initiation when severe immune suppression
has not yet occurred, with some current guidelines* Correspondence: jsempa@idi.co.ug
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reproduction in any medium, provided the orrecommending a threshold below 500 cells/μl for initiat-
ing cART [5,6].
Despite the evidence of the benefits of early initiation
of ART [7,8]in sub-Saharan Africa, where the HIV pan-
demic is most severe, cART is usually commenced at
later stages of the disease and often after the onset of
Acquired Immune Deficiency Syndrome (AIDS) [9]
when the risk of death is much higher [10].
In 2010, the World Health Organization (WHO)
recommended earlier initiation of cART for HIV-
infected patients in developing countries [11]. The im-
munologic threshold for cART initiation was increased
from a CD4+ T cell (CD4) count of 200 cells/μL to 350
cells/μL, effectively increasing the number of patients
eligible for cART. Importantly, at the end of 2010, onlyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tually accessing cART based on the prior WHO cut-off
of 350 cells/μL [12]. In Uganda, where approximately 1.2
million people are infected with HIV, WHO recommen-
dation were adopted and the national guidelines recom-
mend to increase the threshold from 250 to 350 cells/μL
[13]. However, in 2009, only 53.5% of Ugandan adults
with CD4 count below 250 cells/μL were receiving cART
[14] and with the current WHO and National recom-
mended ART eligibility criteria of CD4 count < 350 cell/
μL [11,13],the coverage of ART drops to 47% [13]. Add-
itionally, adoption of the 2010 revised WHO guidelinesTable 1 Model Inputs for the patient characteristics and cost
Input Value
Life Expectancy, in years
CD4 = 50-200 9.60
CD4 = 200-350 19.30
CD4 tests per year 2




Years of AIDS before death 1
Annual Number of Inpatient Days with OIb,c
CD4 > 350 (on cART) 0.37
CD4 > 350 (off cART) 5.7
CD4 = 201-350 (on cART) 0.52
CD4 = 201-350 (off cART) 10.8
Annual Number of Inpatient Days without OIb,c
CD4 > 350 (on cART) 0.14
CD4 > 350 (off cART) 1.9
CD4 = 201-350 (on cART) 0.39
CD4 = 201-350 (off cART) 3
Costs
cART drug cost, per yeard $192.44
cART maintenance cost, year $113.40
Total Treatment cost, sum $305.84






Cost per Inpatient Day $31.48
Discount Rate 3%
aDALY - Disability Adjusted Life Years.
b OI – Opportunistic infections.
c The sensitivity range is not reported in[23]. In our model, we assume a 50% decre
dcART- combination antiretroviral therapy, containing: AZT – zidovudine ; 3TC – lamis expected to increase the number of patients on cART
and the work load of HIV programs, and consequently
increase costs associated with cART provision [15]. In
general, the adoption of the WHO recommendations
seems to be delayed in countries with relatively low
health expenditure per capita and as well as low gross
domestic product per capita, and costs associated with
availability of cART is often cited as a reason for delayed
initiation of cART [16]. In resource-constrained settings,
like Uganda, evidence of the cost-effectiveness of these
new guidelines is needed to inform policy and to support


























ase and 50% increase in OI’s relative to the base case.
ivudine; EFV- efavirenz.
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of initiating cART in patients using the revised CD4
count threshold of 350 cells/μL as in the WHO 2010
guidelines versus (vs) cART initiation using a threshold
of 250 cells/μL.Methods
Model overview
A decision analytic model was used to calculate the dis-
ability adjusted life expectancy for patients with CD4
count between 250 and 350 cells/μL under two treat-
ment scenarios: A, initiate cART immediately and B,
hold cART initiation until the CD4 count falls below
250 cells/μL. In our analysis, we used the standard cost
per disability adjusted life years (DALY’s) metric. The
DALY is defined as the sum of years of life lost (YLL),
and years lived with disability (YLD) [18]. Net costs were
defined as the sum of discounted lifetime treatment cost
associated with cART, including drug and patient moni-
toring costs, and the hospitalization costs with and with-
out severe opportunistic infections within the first 24
months after initiation of therapy. Based on published
sources, we calculated the life expectancy of patients ini-
tiating cART with baseline CD4 count between 250
cells/μL and 350 cells/μL. Patients who initiated treat-
ment immediately (Scenario A) were assigned a life ex-
pectancy [19]; patients who initiated cART after their
CD4 count fell below 250 cells/μL (Scenario B) were
assigned another lower life expectancy which we defined
as the sum of the waiting time plus the life expectancy
associated with the lower baseline CD4 count at initi-
ation of therapy [19] (see more detailed explanations of
the model inputs and outputs below). Select inputs were










Figure 1 Modeled Life Expectancy by baseline CD4 cell count at initia
expectancy data from [18]. **Note: Our continuous life expectancy curve dall calculations were performed in Excel 2007 (Microsoft
Corporation, Redmond, WA, USA).
Model inputs
Model inputs used in this analysis are displayed in
Table 1. Estimates derived from a systematic analysis
using Markov modeling of cART survival data for a
hypothetical Tanzanian population from 20 observa-
tional studies and cohort analyses serve as the basis for
our modeling of conditional life expectancies in Uganda
[19]. We used this approach as similar life expectancy
estimates are not available for Uganda and the two
countries are fairly comparable with respect to a number
of health related parameters such as life expectancy at
birth and HIV prevalence [27]. In the Tanzanian analysis,
life expectancy of patients was positively related to base-
line CD4 count at the time of therapy initiation, even
after taking into consideration the lead-time bias.
Patients who initiated cART at different CD4+ T cell
count levels, 200 cells/μL −350 cells/μL, 50 cells/μL
−199 cells/μL and <50 cells/μL, had an life expectancy
of 19.3, 9.6 and 7.9 years, respectively [19]. In our model,
we subdivided the baseline CD4+ T cellrange of interest
(250–350) into 10 more narrow uniformly distributed
intervals, ranging from 250–259 cells/μL to 340-350
cells/μL. Assuming that the relationship between base-
line CD4+ T cell count and life expectancy is linear and
assuming that the three life expectancy point estimates
apply to the midpoints of these ranges (e.g. 275 cells/μL,
125 cells/μL, and 25 cells/μL), we calculated life expect-
ancies for patients in 10 cells/μL increments between
50-59and 340-350by linear extrapolation (see Figure 1).
For patients in scenario B, who are not immediately
initiated on cART, we assumed a median annual CD4
count reduction of 91.5 cells/μL [21], with an inter-19.30
tion of therapy, in years*. *The bars represent published life
oes not intersect the three bars because we apply a 3% discount rate.
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Since CD4 count is generally measured twice per year
in resource-limited settings like Uganda [20], this trans-
lates into a median biannual CD4 count reduction of 45.8
cells/μL (IQR: 30.7-62.4 cells/μL) in our model. Further-
more, we assumed that patients not meeting the 250
cells/μL threshold would have to wait six months until the
next CD4 count measurement. Upon initiation of cART,
immune reconstitution in the first year was assumed to
occur at a rate of 114 cells/μL per year [21].
The burden of opportunistic infections (OIs) and non-
AIDS diseases in our study population was based on an
analysis conducted among HIV-positive patients in
southern Africa [23]. In this study, the average annual
number of inpatient days with and without severe op-
portunistic disease were reported for HIV-positive
patients conditional on their CD4 count (200–350 cells/
μL; and greater than 350 cells/μL) and conditional on
treatment with cART (see Table 1). The annual number
of expected inpatient days in our scenario A vs scenario
B was calculated for a period of two years in four 6-
month intervals and multiplied by the average cost per
bed day in a tertiary level hospital, including food and
drugs, which for Uganda is reported at $31.5 per day
[26]. All cost used in our analysis were computed in
2011 United States dollars ($).
The cost of first-line cART in Uganda, consisting of zi-
dovudine, lamivudine and either efavirenz or nevirapine
was estimated at $192 per year [28]. The annual costs of
healthcare-related services associated with patient moni-
toring while on cART were obtained from published
sources [28], and included clinic personnel (based on
monthly office visits): $43.0, laboratory costs: $35.0,
other medications: $33.7, and radiology: $1.7. Based on
these costs, we calculated the total annual cost to the
health care system for a patient who is initiated on
cART at $306. In comparison, HIV-positive patients with
CD4 count exceeding the current limit of 250 cells/μL
are also routinely followed up and incur annual costsFigure 2 Structure of the model.including clinic personnel (based on quarterly office vis-
its): $14.3, laboratory costs: $35.0, other medications:
$33.7, and radiology: $1.7. Thus, the average annual
costs of waiting to qualify for cART are estimated at
$84.8. Lifetime HIV treatment costs were therefore
defined as the sum of 1) lifetime first line cART, 2) life-
time patient monitoring, and 3) the cost of OI related
hospitalizations in the first 2 years after therapy initi-
ation. A disability weight of 0.1 was used for each year
lived with HIV and a disability weight of 0.5 was used
for the last year of life with AIDS [22]. All costs and
benefits were discounted at 3% annually [18].
Model structure
In our model, we calculated the life expectancy condi-
tional on baseline CD4 count for the ten CD4 count
increments from 250–259 cells/μL to 340–350 cells/μL.
For patients in scenario A, these represent their dis-
counted life expectancies. Patients in scenario B were
assigned another, lower, life expectancy which we
defined as the sum of the waiting time plus the life ex-
pectancy associated with the lower baseline CD4 count
at initiation of therapy. We calculated their baseline
CD4 count at cART initiation by subtracting 45.8 cells/
μL per 6 month until their CD4 count fell below the
threshold of 250 cells/μL. For example, a patient in sce-
nario B with a CD4 count of 265 cells/μL would have to
wait 6 months and start therapy at about 219 cell/μL.
His life expectancy is therefore 6 months plus his life ex-
pectancy associated with initiation of cART at 219 cells/
μL. However, as shown above, 25% of patients in our
model experience either a slower or faster CD4 count
decline. Therefore, we varied the time to initiation of
cART used in our model by the lowest (25th percentile),
mean (50thpercentile) and highest (75th percentile) CD4
count decline rates. We then calculated YLL as the dif-
ference in the discounted life expectancies between the
two groups, whereas YLD were calculated as the differ-
ence in disability weighted life expectancy between the
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costs between the two scenarios was computed as the
difference in the respective sums of discounted cART
drug and monitoring costs, OI and non-AIDS related
hospitalization costs (see Figure 2).
Results
Life expectancy
Model results are displayed in Table 2. In HIV-positive
patients with a baseline CD4 count ranging from 250–
350 cells/μL, mean life expectancy with immediate initi-
ation of cART (Scenario A) was approximately 20.9
years (discounted: 14.7 years), and varied from as low as
18.0 years (discounted: 13.9 years) to as high as 23.9
years (discounted: 17.0 years).
Based on current guidelines, HIV-positive patients
would have to wait until their CD4 count falls below the
threshold of 250 cells/μL (Scenario B). In our model, theTable 2 Projected estimates associated with each scenario
Baseline CD4 count
Life Expectancy, in years Lowest (250–259)
Mean (250–350)
Highest (340–350)












Lifetime Cost, cART + Monitoring Lowest (250–259)
Mean (250–350)
Highest (340–350)
24 Months Hospitalization Cost Lowest (250–259)
Mean (250–350)
Highest (340–350)
Net Cost Lowest (250–259)
Mean (250–350)
Highest (340–350)
Cost per DALY Lowest (250–259)
Mean (250–350)
Highest (340–350)
cART- combination antiretroviral therapy; YLD – Years Lost due to Disability; DALY -waiting time until initiation of cART for patients with
CD4 count above 250 cells/μL but below 350 cells/μL
ranged from a minimum of 6 months to a maximum of
18 months. By the time cART was initiated, the median
CD4 count in this group had fallen to 226 cells/μL
(IQR:216–234 cells/μL). The ensuing mean life expect-
ancy of 17.0 years (discounted: 13.3 years) varied from a
low of 15.5 years (discounted: 12.41 years) to a high of
17.4 years (discounted: 13.5 years). Our model found
that the waiting strategy (scenario B) was associated with
an average of 2.2 YLL lost, which translated into 1.98
DALY’s.
In our model, all patients in scenario B initiated ther-
apy within 6–18 months from the date of their first CD4
count record ranging between 250 cells/μL −350 cells/
μL. However, by the time of cART initiation, the net life
expectancy associated with the now lower CD4 count




























Disability Adjusted Life Years.
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some monitoring costs were still incurred. In addition,
35%-40% of these short-term savings were offset by
increases in the costs of treating opportunistic
infections.
Treatment costs and cost-effectiveness
Mean lifetime HIV drug and monitoring costs for
patients in Scenario A were $4,744 and ranged from a
low of $4,255 for patients in the lowest CD4 count range
of 250–259 cells/μL to $5,210 for patients in the highest
CD4 count range of 340–350 cells/μL. The mean cost of
hospitalizations in the first 24 months with and without
severe opportunistic infections in this group accounted
for an additional $42 (range: $38 to $45), yielding net
lifetime costs of $4,786 (Range: $4,300 to $5,248). In
comparison, Scenario B patients incurred lifetime HIV
drug and monitoring costs of $3,885 (range: $3,686 to
$3,870) and hospitalization costs of $389 (range: $254
to $565), yielding net costs of $4,274 (range: $3,940 to
$4,435). Thus, in patients with a CD4 count of 250–350
cells/μL, immediate initiation of cART versus waiting
until they meet the current CD4 count threshold of 250
cells/μL was expected to increase lifetime treatment
costs by an average of $512 (Range: $360 to $814) and
was associated with a cost/DALY of $260 (range: $262-
$270).
Sensitivity analyses
We used the mean cost/DALY of $260 as the base-case
for the sensitivity analyses. Varying select model inputs
had no discernible impact on our cost/DALY estimate.
The results obtained in the various one-way sensitivity
analyses are displayed in the tornado diagram in Figure 3.
The incremental cost-effectiveness ratio(ICER) was most
sensitive to the annual cost of ART and annual cost of
ART maintenance. The number of hospitalizations, daily
hospitalization costs, discount rate, CD4 count average de-
cline, annual cost of patient monitoring, and remaining
life expectancy did not have a significant impact on the
ICER.
Discussion
To our knowledge, this is the first study to evaluate the
cost-effectiveness of early cART initiation taking in ac-
count that in resource-limited settings pre-cART CD4
count measurements frequency (every 6 months). We
incorporated the usual waiting time in Uganda into a de-
cision analytic framework to model the clinical and eco-
nomic impact of a hypothetical choice: whether or not
to initiate cART immediately, in this patient population
with CD4 counts between 250 and 350 cells/μL.
Our model shows that initiation of cART among
patients with higher CD4 count (250 – 350 cells/μL) isassociated with an average cost per DALY averted of
$260. According to WHO cost-effectiveness analysis
guidelines for resource-constrained settings, an interven-
tion is highly cost-effective if it is associated with a cost/
DALY less than one time per capita GDP [18]. Annual
per capita GDP in Uganda is $490 per year [28]. Thus,
we conclude that early initiation of first-line cART
among patients with CD4 count from 250 – 350 cells/μL
is highly cost-effective.
Comparable studies in this area have simulated HIV
disease progression using Markov models, were gener-
ally conducted in higher cost settings within sub-
Saharan Africa, and were often conducted at times when
antiretroviral drugs were still priced higher than they are
today. Nevertheless, these studies also found that it is
cost-effective to initiate therapy at CD4 count below 350
cells/μL compared to 200 or 250 cells/μL, with an in-
crease in life expectancy ranging from 0.8-2.3 years (dis-
counted), an incremental lifetime cost of $ 924-$8936
and a cost/QALY of $ 766-$3885 [29-32]. In comparison
to these previous studies, our results present greater
benefits and lower costs associated with earlier com-
mencement of cART, in part, due to ongoing reductions
in the cost of cART in developing countries [33,34].
There are additional benefits associated with early ini-
tiation of cART like a decrease in the HIV transmission
risk resulting from a decreased viral load which we did
not take into account as recent evidence showed that
among discordant couples, cART resulted in a 96% de-
crease in the risk of horizontal HIV transmission [3].
Thus, by only including health benefits as they apply to
the treated patient and ignoring the public health impact
of a decrease in the risk of HIV-transmission, our model
underestimates the actual cost-effectiveness of earlier
commencement of cART. In addition, there is mounting
evidence that earlier initiation of cART also averts non-
HIV associated morbidity (e.g. cardiovascular and renal
events) that we did not factor into our model because
data from resource-limited settings has not yet been
generated [35,36].
Our findings provide supportive evidence for advocacy
and changes in health policy to increase cART funding
in order to make this treatment available to a greater
number of patients. Currently, in Uganda as well as in
other developing countries, cART provision is largely
dependent on foreign donors. International funding for
HIV programs have stagnated or even decreased in the
recent years [37]. However, recent work suggests that
the HIV epidemic can be reversed if an investment
framework is instituted that involves basic programs in-
cluding cART provision [38]. While we emphasize that a
cost-effective intervention may not necessarily be afford-
able in an environment where potentially multiple cost-
effective interventions compete for scarce resources, this
Basecase: $260/DALY


























Figure 3 One-way Sensitivity Analyses of Key Parameters (Basecase Values). AC1: Annual cost of cART ($192.44): $100-$300; AC2: Annual cost
of cART maintenance ($113.40): $50-$200; IH: Number of inpatient hospitalizations (as per Bendavid et al., Ref: 22): -50%/+50%; HC: Daily
Hospitalization Cost ($31.48): $15.74-$47.22; DR: Discount Rate (3%): 0%-6%; CD4: Average CD4 decline in 6 months (45.75): 30.65-62.35; AC3:
Annual costs of patient monitoring while not yet on cART ($84.76): $0-$150; LE: Remaining life expectancy (as per Johansson, Ref: 18): -15%/+15%.
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initiation would likely constitute a highly cost-effective
use of scarce resources. Given the apparent health and
economic benefits of earlier initiation of cART, efforts
should be intensified to provide increased and sustain-
able levels of funding to support cART provision.Limitations
Our analysis was not without limitations. First, life ex-
pectancy estimates on which this analysis is based were
not derived from a randomized clinical trial but were
obtained from a published analysis that extrapolates an-
nual survival data from 20 observational studies and co-
hort analyses using Markov modeling and reports life
expectancies for three baseline CD4 count categories
[19]. Furthermore, in our model we assume a linear rela-
tionship between life expectancy and baseline CD4
count over the range of 250–349 cells/μl at the initiation
of cART. This might lead to overestimation of the health
economic benefit of early cART initiation in patients
with CD4 count on the high end of this range if the ab-
solute increase in life-expectancy were to diminish with
higher baseline CD4 count. Also, we did not include fail-
ure of first-line cART in our model, which would neces-
sitate progression to second-line cART. Second-line
antiretroviral drugs are substantially more expensive and
may therefore potentially have a significant have an im-
pact on our results. However, there is no evidence to
suggest that the rate of first-line treatment failure wouldbe expected to differ between our two treatment arms.
In addition, the rate of cART treatment failures requir-
ing a switch to second line therapy is reported to be
relatively low in Uganda (<1% annually) [39]. Lastly, we
did not include the impact of adherence in our model.
Patients starting cART earlier may be asymptomatic and
have less incentive to take their medication than patients
in whom cART initiation is delayed [40]. Conversely,
delaying cART may put patients at risk of severe oppor-
tunistic infections which may impair adherence by in-
creasing pill burden or by directly affecting cognitive
function. The ultimate impact of adherence on our cost-
effectiveness ratio is therefore unclear and further re-
search is warranted.
Conclusion
In summary, immediate initiation of cART is highly
cost-effective in HIV-positive patients presenting with
CD4 count between 250–350 cells/μl in Uganda.
Expanding the number of treatment slots to include
patients with higher CD4 count would be an efficient
use of scarce health care funds.
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